loxoprofen has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, A | 2 |
| Ebihara, S | 2 |
| Takahashi, H | 1 |
| Sasaki, H | 2 |
| Okazaki, T | 1 |
| Yasuda, H | 1 |
2 other studies available for loxoprofen and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Lewis Lung; Carc | 2003 |
Loxoprofen sodium and survival in older people with advanced non-small cell lung cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung | 2004 |